Abstract
The extensive use of the same chemotherapeutics over several decades has resulted in a growing incidence of chemoresistant cancer cells and secondary malignancies. Therefore, there is an increasing need for new drugs to treat high-risk cancer patients with a higher selectivity for cancer cells and lower toxicity to normal cells. Sulforaphane is released upon hydrolysis of glucoraphanin, a constituent of cruciferous vegetables, by myrosinases that are present in the plant or intestinal microbes. Despite a large number of studies describing the chemopreventive and chemotherapeutic properties of sulforaphane in solid tumors, there is little information on the properties of sulforaphane in hematological malignancies. In this review, we discuss the anti-carcinogenic properties of sulforaphane, the need of higher doses than dietary intake, and the challenges related to testing sulforaphane as an adjunctive agent in combination with the current standard of care for frontline blood cancer.
Keywords: Animal model, cancer, clinical trial, leukemia, natural product, sulforaphane, therapy.
Current Cancer Drug Targets
Title:From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Volume: 14 Issue: 5
Author(s): Koramit Suppipat and H. Daniel Lacorazza
Affiliation:
Keywords: Animal model, cancer, clinical trial, leukemia, natural product, sulforaphane, therapy.
Abstract: The extensive use of the same chemotherapeutics over several decades has resulted in a growing incidence of chemoresistant cancer cells and secondary malignancies. Therefore, there is an increasing need for new drugs to treat high-risk cancer patients with a higher selectivity for cancer cells and lower toxicity to normal cells. Sulforaphane is released upon hydrolysis of glucoraphanin, a constituent of cruciferous vegetables, by myrosinases that are present in the plant or intestinal microbes. Despite a large number of studies describing the chemopreventive and chemotherapeutic properties of sulforaphane in solid tumors, there is little information on the properties of sulforaphane in hematological malignancies. In this review, we discuss the anti-carcinogenic properties of sulforaphane, the need of higher doses than dietary intake, and the challenges related to testing sulforaphane as an adjunctive agent in combination with the current standard of care for frontline blood cancer.
Export Options
About this article
Cite this article as:
Suppipat Koramit and Lacorazza Daniel H., From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?, Current Cancer Drug Targets 2014; 14(5) . https://dx.doi.org/10.2174/1568009614666140521142950
DOI https://dx.doi.org/10.2174/1568009614666140521142950 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Study of Common Bacterial and Fungal Pathogens in Children with Hematological Malignancies during Febrile Neutropenia: Single Center Egyptian Study
Infectious Disorders - Drug Targets A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Neopterin as a Marker for Immune System Activation
Current Drug Metabolism NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Preclinical and Clinical Studies on the Use of Platinum Complexes for Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Inhibition of PCAF by Anacardic Acid Derivative Leads to Apoptosis and Breaks Resistance to DNA Damage in BCR-ABL-expressing Cells
Anti-Cancer Agents in Medicinal Chemistry Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases
Mini-Reviews in Medicinal Chemistry Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment
Current Drug Targets An Updated Review of Natural Products Intended to Prevent or Treat Oral Mucositis in Patients Undergoing Radio-Chemotherapy
Current Pharmaceutical Biotechnology Pharmacogenomic Approaches for Tailored Anti-Leukemic Therapy in Children
Current Medicinal Chemistry Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Current Medicinal Chemistry Targeted Multifunctional Lipid-Based Nanocarriers for Image-Guided Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry Rational Drug Design of G-Quartet DNA as Anti-Cancer Agents
Current Pharmaceutical Design Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets A Prooxidant Mechanism for the Anticancer and Chemopreventive Properties of Plant Polyphenols
Current Drug Targets Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
CNS & Neurological Disorders - Drug Targets